Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C138996
http://purl.obolibrary.org/obo/NCIT_C138996
|
|---|---|
| Preferred Name | Icotinib |
| Definitions |
An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types. |
|---|---|
| prefLabel | Icotinib
|
| label | Icotinib
|
| Has_Salt_Form | |
| NCI_META_CUI | CL433010
|
| code | C138996
|
| prefixIRI | NCIT:C138996
|
| in_subset | |
| Preferred_Name | Icotinib
|
| FDA_UNII_Code | 9G6U5L461Q
|
| Contributing_Source | FDA
|
| CAS_Registry | 610798-31-7
|
| type | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |